Newsroom

Feb 1, 2022, Sera announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.

Dec 15, Sera announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

Dec. 2, 2021, Sera announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.

Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.

Nov. 30, 2021, Sera announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.

Nov 8,2021, Sera announced that Zhenya Lindgardt has joined the Sera Board of Directors.

Nov. 4, 2021, Sera announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

November 3, 2021, Sera announced the publication of a rigorous  validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the company’s PreTRM® test.

Nov. 2, 2021, Sera announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, leading organizations all geared to empowering and supporting families impacted by preterm birth.

October 27, 2021- The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time.